CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price of $9.00 per share, before underwriting discounts. In addition, Epizyme has granted the underwriter a 30-day option to purchase up to an additional 1,250,000 shares of common stock at the public offering price, less the underwriting discount. All of the shares in the offering are to be sold by Epizyme.

Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $75.0 million, excluding any potential exercise of the underwriter’s option to purchase additional shares.

Epizyme anticipates using the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities to fund global development and commercialization costs of tazemetostat outside of Japan, including the costs of Epizyme’s ongoing and planned clinical trials of tazemetostat, the costs of regulatory activities related to tazemetostat, including associated milestone payments, and the costs associated with the commercial launch of tazemetostat for epithelioid sarcoma, if approved; to fund research and development costs to develop other product candidates, including EZM8266 for sickle cell disease; and for working capital and other general corporate purposes.

Jefferies is acting as sole book-running manager for the offering. The offering is expected to close on or about October 5, 2018, subject to customary closing conditions.

About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them.